Cybin: A Speculative Bet On Their Pivotal Depression Readout

Impact · against what's priced in

The upcoming Phase 3 APPROACH readout for HLP003 serves as the primary near-term catalyst for Cybin. Recent fundraising and a debt-free balance sheet mitigate solvency risks leading up to the Q4 2026 results.

CYBN+0.60

No priced-in read yet

In context

The market faces a binary event in Q4 2026 with the Phase 3 APPROACH readout for HLP003, supported by a clean balance sheet and recent June 2026 funding.

Read from the article alone

• biotech
• CYBN
• anxiety
• clinical trials
• depression
• fundraising
• phase 3

Search tags